GenomeWeb

Renowned Scientist Christopher Mason, Ph.D. and Quantum-Si Collaborate for Exclusive GenomeWeb Webinar

Retrieved on: 
Tuesday, February 27, 2024
Technology, Biotechnology, Health, Other Health, Pharmaceutical, Oncology, Other Science, University, Research, Education, Genetics, Hardware, Science, Semiconductor, Survival, Disease, Extremophile, Biology, GenomeWeb, Weill Cornell Medicine, Dicarboxylic acid, Acceleration, Proteomics

WHAT: Esteemed scientist Christopher Mason, Ph.D., of Weill Cornell Medicine, is set to discuss his Two Frontiers Project during an exclusive webinar hosted by GenomeWeb.

Key Points: 
  • WHAT: Esteemed scientist Christopher Mason, Ph.D., of Weill Cornell Medicine, is set to discuss his Two Frontiers Project during an exclusive webinar hosted by GenomeWeb.
  • Dr. Mason will also reveal his plans for using Quantum-Si’s benchtop protein sequencer, Platinum® to expand his multiomic research on extremophiles and what is needed for human survival in extreme environments.
  • WHY: Dr. Mason recently remarked, “To better understand disease and health, we must not only look at nucleic acids, but also other molecules and pivotal proteins.
  • We are now experiencing a remarkable acceleration with advancements in protein sequencing, revealing new biology and post-translational modifications.”
    WHEN: The webinar, titled “Characterizing Far-Flung Extremophiles with Next-Generation Protein Sequencing™,” will take place on Wednesday, February 28, at 11:00 a.m.

RT MicroDx Founder & CEO Nathalya Mamane to Present at Biotech Showcase During JPM Week

Retrieved on: 
Tuesday, January 2, 2024
Conference, Saliva, Boston Business Journal, FDA, Strep, GenomeWeb, Health, DNA, PCR, Group A streptococcal infection, Mass, Entrepreneurship, RT, Pacific Time Zone, Babson College, Infection, Sleep hygiene, Pharmaceutical industry

BOSTON, Jan. 2, 2024 /PRNewswire-PRWeb/ -- RT MicroDx, a biotech company working to develop a technology platform for affordable, accurate, at-home molecular diagnostics, announced today that its founder and CEO, Natalya Mamane, will be presenting at the Biotech Showcase conference, to be held January 8th through 10th at the Hilton San Francisco Union Square in San Fransisco, CA. The event connects investors and micro-mid-cap biotechnology companies, providing a unique platform for biotech companies to showcase their innovations and engage one-to-one with investors and biopharmaceutical executives. RT MicroDx's technology and diagnostic tests are in prototype stage and have not been evaluated or approved by the FDA.

Key Points: 
  • The event connects investors and micro-mid-cap biotechnology companies, providing a unique platform for biotech companies to showcase their innovations and engage one-to-one with investors and biopharmaceutical executives.
  • RT MicroDx's technology and diagnostic tests are in prototype stage and have not been evaluated or approved by the FDA.
  • - Nathalya Mamane, Founder & CEO
    "The events surrounding the annual J.P. Morgan Healthcare Conference, including the Biotech Showcase conference, are an opportunity to network and share ideas with some of the most brilliant minds in biotech, and I'm thrilled to take part," said Mamane.
  • RT MicroDx's technology and diagnostic tests are in prototype stage and have not been evaluated or approved by the FDA,
    To schedule a meeting with Mamane at the Biotech Showcase conference, email: [email protected] .

Form Bio Announces First Half 2023 Achievements

Retrieved on: 
Wednesday, August 9, 2023
Software, Research, Pharmaceutical, Data Management, Technology, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Health, Cloud, Maker, Molecule, Workforce, Organization, MED, Publication, NVIDIA, Google Cloud, GenomeWeb, Drug discovery, Growth, Entrepreneurship, AI, Stat (website), Industry Dive, SXSW, News, Rare-earth element, Pharmaceutical industry, Fine chemical

Form Bio , the breakthrough AI-powered drug discovery platform, announced today its notable achievements and product advancements for the first half of 2023.

Key Points: 
  • Form Bio , the breakthrough AI-powered drug discovery platform, announced today its notable achievements and product advancements for the first half of 2023.
  • The company’s strong performance sets the stage for continued growth as Form Bio prioritizes the development of its technology and workforce.
  • “Form Bio plays a crucial role in driving the adoption of AI in life sciences, specifically in the field of cell and gene therapies,” said Kent Wakeford, Co-Founder and Co-CEO of Form Bio.
  • PacBio : Form Bio announced it joined the PacBio Compatible Program to accelerate gene therapy research from data to insights.

Fluent BioSciences Partners with GenomeWeb and NYU Grossman School of Medicine's Liddelow Lab to Host Webinar on Revolutionary PIPseq scRNA-Seq Technology with Upcoming bioRxiv Publication

Retrieved on: 
Wednesday, May 17, 2023
Shelly Liddelow, Central nervous system, EST, Fluency, Laboratory, RNA, GenomeWeb, CNS, Vaccine

The Liddelow Lab has successfully deployed PIPseq for use in examining central nervous system (CNS) cells across a range of acute inflammation and genetic labeling models for high-throughput single-cell analysis in the mouse brain.

Key Points: 
  • The Liddelow Lab has successfully deployed PIPseq for use in examining central nervous system (CNS) cells across a range of acute inflammation and genetic labeling models for high-throughput single-cell analysis in the mouse brain.
  • The webinar will discuss an upcoming publication from the Liddelow Lab demonstrating how the PIPseq technique can accelerate single-cell research and showcase their successful deployment of PIPseq for CNS analysis.
  • "We are thrilled to partner with the Liddelow Lab and GenomeWeb to host this webinar and share our groundbreaking PIPseq technology with the scientific community," said Brian Mckernan, CEO of Fluent BioSciences.
  • The webinar is scheduled for May 18th,1pm EST and will feature a presentation from Dr. Shane Liddelow.

Prominent oncologist to discuss advantages of Oxford BioDynamics’ EpiSwitch CiRT at the 2022 Liquid Biopsy Virtual Summit

Retrieved on: 
Monday, November 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Hospital, Massachusetts General Hospital, Liquid biopsy, Genomics, Checkpoint, Pfizer, Oncology, Systems biology, Biotechnology, CST, Precision medicine, Prognosis, OBD, London, Patient, Mitsubishi Tanabe Pharma, Merck Serono, London Stock Exchange, Biogen, Marie Cassidy, Cancer, Architecture, Biomarker, Research, Immune system, ICI, Mayo Clinic, CIRT, Disease, EST, GenomeWeb, Roche, 3D, AIM, COVID-19, Genome, Medical imaging, Pharmaceutical industry, Genentech, MD

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch 3D genomics platform, announces that prominent medical oncologist, Dr. Steven Mamus, a regular user of EpiSwitch CiRT, will be speaking about OBDs flagship test at the 2022 Liquid Biopsy Virtual Summit, 6 December 2022.

Key Points: 
  • Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch 3D genomics platform, announces that prominent medical oncologist, Dr. Steven Mamus, a regular user of EpiSwitch CiRT, will be speaking about OBDs flagship test at the 2022 Liquid Biopsy Virtual Summit, 6 December 2022.
  • OBD will also have a virtual booth with information and educational materials for the EpiSwitch CiRT.
  • The virtual event is scheduled for December 6, 2022, from 10:00 am to 3:00 pm EST.
  • Built on over 10 years of research, EpiSwitch is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers.

Science & Medicine Group Announces Top Life Science Editors to Lead LabPulse and The Science Advisory Board

Retrieved on: 
Tuesday, October 18, 2022
SMG, Medicine, General manager, Growth, GenomeWeb, Publishing, Gold Award, Society, National Science Advisory Board for Biosecurity, Intelligence, Wiley (publisher), Editorial, Publication, Science Advisory Board, Pharma, Knowledge, SAB, Frost, Frost & Sullivan, Drug discovery, Industry, CEO, Marie Cassidy, Research ethics consultation, Bioinformatics, Solution, Pharmaceutical industry, Fine chemical, Kalorama, Science, Research

ARLINGTON, Va., Oct. 18, 2022 /PRNewswire/ -- Science and Medicine Group Inc. (SMG), a data intelligence company providing actionable insights about hard-to-reach audiences in the life sciences and healthcare, today announced the appointments of Leo O'Connor as Editor in Chief of LabPulse, and Greg Slabodkin as Editor in Chief of The Science Advisory Board. With decades of industry experience, these editorial leaders will support the expansion of two popular SMG-owned data and intelligence resources known for providing insights about scientific advancements, collaborations and trends across key market segments, including life science research, clinical laboratories, pharma, and biotech.

Key Points: 
  • The Science Advisory Board is an international community of life science and medicine experts immersed in biological research, drug discovery and biopharmaceutical production.
  • The Science Advisory Board is also a channel for researchers, professionals, trainees and advocates to stay on top of life science and biopharmaceutical news and trends.
  • "The Science Advisory Board community is one of the most intellectually stimulating, diverse and impressive groups of experts shaping the future of life science and drug discovery and development," said Slabodkin.
  • For more information about LabPulse, go to: www.labpulse.com
    For more information about Science Advisory Board, go to: www.scienceboard.net
    Science and Medicine Group is on a mission as a premier data intelligence company to deliver actionable insights about hard-to-reach audiences in science and medicine.

EDGC (Eone Diagnomics Genome Center) recruits Sam Martin, Vice President of Overseas Business Development... to "accelerate entering the overseas market"

Retrieved on: 
Tuesday, September 13, 2022
Precision medicine, Genetic counseling, Beth Israel Hospital, Liquid biopsy, Industry, Genetics, Cancer, Non-functional testing, GenomeWeb, Technology, Diagnosis, SAN, Multimedia, Video game, Invitae, American, KOSDAQ

By recruiting Sam Martin, who has a wealth of experience and network in the overseas genome market, EDGC will make a full-scale entry into overseas markets and solidify its status as a global bio company.

Key Points: 
  • By recruiting Sam Martin, who has a wealth of experience and network in the overseas genome market, EDGC will make a full-scale entry into overseas markets and solidify its status as a global bio company.
  • Sam Martin is an American Board-Certified Genetic Counselor who holds multiple master's degree in human genetics/genetic counseling and software engineer and design from the United States.
  • He recently worked for Invitae and Ambry genetics, two of the top US genetics companies specializing in personal genomic medicine.
  • He also has clinical experience as a genetic counseling, working eight years at Beth Israel Hospital in New York City.

Personalis Announces Expansion of Its Patent Portfolio Related to Tumor-Informed Detection of Molecular Residual Disease

Retrieved on: 
Tuesday, July 12, 2022
Software, Radiology, Hardware, Pharmaceutical, Data Management, Oncology, Technology, Infectious Diseases, Genetics, Surgery, Clinical Trials, Biotechnology, Health, Sequence, Method, GenomeWeb, U.S. Securities and Exchange Commission, Neoplasm, College, Drug resistance, Leadership, Exome, Solution, Genetics, Mutation, LinkedIn, Genomics, Whole genome sequencing, Patient, CEO, Clinical Laboratory Improvement Amendments, Form, Form S-3, PSNL, College of American Pathologists, Patent, Database, Breast, Cancer, Nasdaq, Plasma, PLOS Genetics, Twitter, MRD, Genome, Immune system, NeXT, Recurrence, Efficiency, DNA, Family, Medical imaging, Chief Justice of Hungary

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013.
  • After a tumor has been surgically resected, it may be present at just a few parts per million.
  • To improve the chances of detecting a signal, data can be combined from several tumor mutation positions in a genome.
  • John West, CEO and co-founder of Personalis, and a co-inventor, said, Personalis was active in whole human genome sequencing very early on.

Karius® Partners with Capstone Health Alliance to Widen Patient Access to Liquid Biopsy Test for Infectious Diseases

Retrieved on: 
Thursday, June 9, 2022
Society, Liquid biopsy, Infection, GenomeWeb, Plasma, Aggregation, Partnership, Awareness, Organization, Multimedia, Bed, Patient, Hospital, DNA, Health, Diagnosis, Twitter, MD, View, Leptospira, Pharmaceutical industry, Vaccine, The New York Times, Loris Karius, Nocardia, Capstone

REDWOOD CITY, Calif., June 9, 2022 /PRNewswire/ -- Karius®, the world leader in liquid biopsy for infectious diseases, today announced a partnership with Capstone Health Alliance, a group purchasing organization focused on supply chain savings in hospitals and other organizations, to streamline patient access to the Karius Test®. The Karius Test is a lab-developed test that can non-invasively and rapidly detect more than 1,000 pathogens throughout the body from a single blood sample. Through the partnership, doctors at over 265 Capstone member hospitals across the U.S. can now more easily order the Karius Test for patients harboring hard-to-diagnose infections.

Key Points: 
  • REDWOOD CITY, Calif., June 9, 2022 /PRNewswire/ -- Karius , the world leader in liquid biopsy for infectious diseases, today announced a partnership with Capstone Health Alliance, a group purchasing organization focused on supply chain savings in hospitals and other organizations, to streamline patient access to the Karius Test.
  • The Karius Test is a lab-developed test that can non-invasively and rapidly detect more than 1,000 pathogens throughout the body from a single blood sample.
  • Capstone and Karius are focused on expanding access to quality medical care especially for patients at high risk, such as those with compromised immune systems.
  • "We are thrilled to partner with Capstone Health Alliance to accelerate access for patients to our metagenomic infectious disease test," said Brad Perkins, MD, Chief Medical Officer of Karius.

VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update

Retrieved on: 
Wednesday, May 11, 2022
Cancer, Quality, Company, Disease, Capital market, Chromatin, Nu, New, 2021 Essex County Council election, Patient, Science, Quality of life, Lung cancer, Point-of-care testing, Proteomics, COVID-19, Point, Research, Mass spectrometry, Epigenetics, Marketing, Life, GenomeWeb, Conference call, NYSE, Software development process, Technology, Sale, Colorectal cancer, NETS, Lung, Animal, Sepsis, Diagnosis, Factor X, Achievement, Video game, Pharmaceutical industry, Sales, Veterinary medicine, Video game console, Medical device, Online shopping, Neutrophil extracellular traps, Conference, Volition, Nucleosome

AUSTIN, Texas, May 11, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2022. Volition management will host a conference call tomorrow, May 12 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

Key Points: 
  • Conference call to discuss financial and operational results scheduled for Thursday, May 12, at 8:30 a.m. U.S. Eastern Time
    AUSTIN, Texas, May 11, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2022.
  • Volition management will host a conference call tomorrow, May 12 at 8:30 a.m. U.S. Eastern Time to discuss these results.
  • Cash and cash equivalents as of March 31, 2022, totaled approximately $23.7 million compared with $20.6 million as of December 31, 2021.
  • The call will provide an update on important events which have taken place in the first quarter of 2022 and upcoming milestones.